Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy

Genes and Cancer

Volumn 4, Issue 7-8, 2013, Pages 247-260

  Xie, Qian ^a   Su, Yanli ^a   Dykema, Karl ^a   Johnson, Jennifer ^a   Koeman, Julie ^a   De Giorgi, Valeria ^b   Huang, Alan ^c   Schlegel, Robert ^c   Essenburg, Curt ^a   Kang, Liang ^a   Iwaya, Keiichi ^d   Seki, Shuhji ^d   Khoo, Sok Kean ^a   Zhang, Boheng ^e   Buonaguro, Franco ^f   Marincola, Francesco M ^b,g   Furge, Kyle ^a   Vande Woude, George F ^a   Shinomiya, Nariyoshi ^d  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

hepatitis B; hepatocellular carcinoma; hepatocyte growth factor; MET; targeted therapy

Indexed keywords

BIOLOGICAL MARKER; MET INHIBITOR; PROTEIN INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HEPATITIS B VIRUS; HGF GENE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER REGENERATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84887414585     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913501075     Document Type: Article

References (38)

1. Whittaker S,Marais R,Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma.Oncogene. 2010;29 (36): 4989-5005.
2. Anzola M.Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis.J Viral Hepat. 2004;11 (5): 383-93.
3. Chisari FV,Klopchin K,Moriyama T,et al.Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989;59 (6): 1145-56.
4. Bladt F,Riethmacher D,Isenmann S,Aguzzi A,Birchmeier C.Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud.Nature. 1995;376 (6543): 768-71.
5. Schmidt C,Bladt F,Goedecke S,et al.Scatter factor/hepatocyte growth factor is essential for liver development.Nature. 1995;373 (6516): 699-702.
6. Uehara Y,Minowa O,Mori C,et al.Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.Nature. 1995;373 (6516): 702-5.
7. Borowiak M,Garratt AN,Wustefeld T,Strehle M,Trautwein C,Birchmeier C.Met provides essential signals for liver regeneration.Proc Natl Acad Sci U S A. 2004;101 (29): 10608-13.
8. Sakata H,Takayama H,Sharp R,Rubin JS,Merlino G,LaRochelle WJ.Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers.Cell Growth Differ. 1996;7 (11): 1513-23.
9. Tward AD,Jones KD,Yant S,et al.Distinct pathways of genomic progression to benign and malignant tumors of the liver.Proc Natl Acad Sci U S A. 2007;104 (37): 14771-6.
10. Wang R,Ferrell LD,Faouzi S,Maher JJ,Bishop JM.Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.J Cell Biol. 2001;153 (5): 1023-34.
11. Fujimoto A,Totoki Y,Abe T,et al.Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.Nat Genet. 2012;44 (7): 760-4.
12. Sung WK,Zheng H,Li S,et al.Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.Nat Genet. 2012;44 (7): 765-9.
13. Ye QH,Qin LX,Forgues M,et al.Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.Nat Med. 2003;9 (4): 416-23.
14. Hoshida Y,Villanueva A,Kobayashi M,et al.Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med. 2008;359 (19): 1995-2004.
15. Kaposi-Novak P,Lee JS,Gomez-Quiroz L,Coulouarn C,Factor VM,Thorgeirsson SS.Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.J Clin Invest. 2006;116 (6): 1582-95.
16. Xie Q,Bradley R,Kang L,et al.Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.Proc Natl Acad Sci U S A. 2012;109 (2): 570-5.
17. Wilson TR,Fridlyand J,Yan Y,et al.Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Nature. 2012;487 (7408): 505-9.
18. Straussman R,Morikawa T,Shee K,et al.Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.Nature. 2012;487 (7408): 500-4.
19. Rong S,Bodescot M,Blair D,et al.Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.Mol Cell Biol. 1992;12 (11): 5152-8.
20. Bhargava M,Joseph A,Knesel J,et al.Scatter factor and hepatocyte growth factor: activities, properties, and mechanism.Cell Growth Differ. 1992;3 (1): 11-20.
21. Zhang YW,Staal B,Essenburg C,et al.MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.Cancer Res. 2010;70 (17): 6880-90.
22. Zhang YW,Su Y,Lanning N,et al.Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.Oncogene. 2005;24 (1): 101-6.
23. Kim SY,Volsky DJ.PAGE: parametric analysis of gene set enrichment.BMC Bioinformatics. 2005;6:144.
24. Lee JS,Chu IS,Mikaelyan A,et al.Application of comparative functional genomics to identify best-fit mouse models to study human cancer.Nat Genet. 2004;36 (12): 1306-11.
25. De Giorgi V,Monaco A,Worchech A,et al.Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma.J Transl Med. 2009;7:85.
26. De Giorgi V,Buonaguro L,Worschech A,et al.Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis.PLoS One. 2013;8 (2): 1-13.
27. Llovet JM,Bruix J.Molecular targeted therapies in hepatocellular carcinoma.Hepatology. 2008;48 (4): 1312-27.
28. You H,Ding W,Dang H,Jiang Y,Rountree CB.c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.Hepatology. 2011;54 (3): 879-89.
29. Huh CG,Factor VM,Sanchez A,Uchida K,Conner EA,Thorgeirsson SS.Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.Proc Natl Acad Sci U S A. 2004;101 (13): 4477-82.
30. Nakamoto Y,Guidotti LG,Kuhlen CV,Fowler P,Chisari FV.Immune pathogenesis of hepatocellular carcinoma.J Exp Med. 1998;188 (2): 341-50.
31. Zhang YW,Su Y,Volpert OV,Vande Woude GF.Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.Proc Natl Acad Sci U S A. 2003;100 (22): 12718-23.
32. Turke AB,Zejnullahu K,Wu YL,et al.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell. 2010;17 (1): 77-88.
33. Huang PH,Mukasa A,Bonavia R,et al.Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.Proc Natl Acad Sci U S A. 2007;104 (31): 12867-72.
34. Eder JP,Vande Woude GF,Boerner SA,LoRusso PM.Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.Clin Cancer Res. 2009;15 (7): 2207-14.
35. Smolen GA,Sordella R,Muir B,et al.Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.Proc Natl Acad Sci U S A. 2006;103 (7): 2316-21.
36. Smyth GK.Linear models and empirical bayes methods for assessing differential expression in microarray experiments.Stat Appl Genet Mol Biol. 2004;3:.
37. Lopez-Romero P.Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library.BMC Genomics. 2011;12:64.
38. Tian J,Tang ZY,Ye SL,et al.New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis.Br J Cancer. 1999;81 (5): 814-21.